The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).
Age ≥ 40 years old on the day of enrollment, gender not limited.
Can provide legal proof of identity.
Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment.
Be able to participate in all planned follow-up visits and comply with all trial procedures.
Individuals with a history of herpes zoster in the past.
Individuals with a history of vaccination against chickenpox or shingles.
Individuals who have had close contact with patients with chickenpox or shingles in the past 2 years.
Women of childbearing age who have a positive urine pregnancy test, are breastfeeding, pregnant, or plan to become pregnant within 6 months after the start of the test and the full exemption period.
10
Treatment groupsSee each treatment group below.